RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500031-37-00

Acronym

UCL/15/0105

Enrollment

289

Registered

2023-07-18

Start date

2024-04-08

Completion date

Unknown

Last updated

2025-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stage IA/IIA Hodgkin lymphoma

Brief summary

Progression-Free Survival (PFS)

Detailed description

PET Complete Metabolic Response (CMR) rate after 2 cycles of ABVD/ A2VD, Event-Free Survival (EFS), Overall survival (OS), Incidence of second cancers and cardiovascular disease, Safety and toxicity of ABVD and A2VD as assessed by CTCAE v5.0

Interventions

DRUGVinblastine Sulfate 1 mg/ml solution for injection

DRUGADCETRIS 50 mg powder for concentrate for solution for infusion

DRUGBleomycin 15000 IU Powder for solution for injection/ infusion

DRUGDacarbazine medac 1000 mg

DRUGpowder for solution for infusion

DRUGDacarbazine medac 100 mg

DRUGpowder for solution for injection/infusion

DRUGFILGRASTIM

DRUGDoxorubicin hydrochloride 2 mg/ml solution for infusion

DRUGDacarbazine medac 200 mg

DRUGDacarbazine medac 500 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS)	—

Secondary

Measure	Time frame
PET Complete Metabolic Response (CMR) rate after 2 cycles of ABVD/ A2VD, Event-Free Survival (EFS), Overall survival (OS), Incidence of second cancers and cardiovascular disease, Safety and toxicity of ABVD and A2VD as assessed by CTCAE v5.0	—

Countries

Belgium, Denmark, Ireland, Netherlands, Portugal, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026